Prelude Therapeutics (PRLD) Presents Preclinical Data for KAT6A Degarader PRT13722 in Breast Cancer

Prelude Therapeutics (NASDAQ:PRLD) is one of the best biotech penny stocks to buy in 2026. On April 20, Prelude Therapeutics presented promising preclinical data for PRT13722, a first-in-class, oral KAT6A degrader. Designed for HR+/HER2- breast cancer, the candidate demonstrated the ability to achieve complete tumor regressions as a monotherapy across multiple models, including those resistant to current endocrine therapies.

Unlike traditional dual inhibitors, PRT13722 specifically targets and degrades the KAT6A protein, a mechanism Prelude believes offers superior efficacy and a significantly improved hematological safety profile. The preclinical findings suggest that PRT13722 is highly synergistic when combined with existing standards of care, such as CDK4/6 inhibitors and PI3Kα inhibitors.

This combinability is a key differentiator, as the degrader maintains its activity even in the presence of acquired therapy-resistant mutations, like ESR1. By selectively degrading KAT6A rather than inhibiting both KAT6A and KAT6B, the company aims to avoid the dose-limiting toxicities often associated with less selective approaches. Prelude Therapeutics (NASDAQ:PRLD) remains on track to file an IND application for PRT13722 by mid-2026.

15 African Countries with the Best Doctors

Prelude Therapeutics (NASDAQ:PRLD) is a precision oncology company developing highly selective KAT6A degraders, JAK2V617F inhibitors, and next-gen degrader antibody conjugates (DACs). The firm uses targeted protein degradation to create transformative therapies for cancer patients with high unmet needs.

READ NEXT: 33 Stocks That Should Double in 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy. 

Disclosure: None. Follow Insider Monkey on Google News.